Figure 5.
RFP knockdown enhances the sensitivity of tumors to carboplatin in vivo; 5 × 106 SKOV3 ovarian cancer cells infected with retroviruses carrying shCont or shRFP were inoculated subcutaneously (s.c.) into nude mice. When tumors reached approximately 50 mm3, 10 mice were treated with phosphate-buffered saline (PBS) or carboplatin (35 or 100 mg/kg) i.p. four times every 2 days. (A) Representative transplanted tumors excised at day 21 are shown. (B) Tumors were measured at different days after PBS or carboplatin treatment, and growth curves were drawn. Tumor volume of the carboplatin-treated shRFP group was significantly smaller than that of the control group. Left, 35 mg/kg carboplatin treatment group; right, 100 mg/kg carboplatin treatment group. (C) The mean tumor volume of the PBS-treated group was defined as 100% and compared with that of the treated group on days 1 and 21. Statistic analysis was performed by Student's t-test. Carboplatin treatment group, n = 5; PBS group, n = 3; bars, SD.